Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
4.09 +0.01 (+0.25%) 09:59 ET [NASDAQ]
4.10 x 500 4.13 x 300
Realtime by (Cboe BZX)
4.10 x 500 4.13 x 300
Realtime 4.00 -0.08 (-1.96%) 09:04 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
4.00
Day High
4.16
Open 4.16
Previous Close 4.08 4.08
Volume 12,664 12,664
Avg Vol 692,191 692,191
Stochastic %K 24.21% 24.21%
Weighted Alpha -13.88 -13.88
5-Day Change -0.04 (-0.88%) -0.04 (-0.88%)
52-Week Range 3.85 - 6.75 3.85 - 6.75
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 237,929
  • Shares Outstanding, K 58,316
  • Annual Sales, $ 198,770 K
  • Annual Income, $ -18,900 K
  • EBIT $ -33 M
  • EBITDA $ -32 M
  • 60-Month Beta 0.72
  • Price/Sales 1.21
  • Price/Cash Flow N/A
  • Price/Book 0.45

Options Overview Details

View History
  • Implied Volatility 131.73% ( +68.03%)
  • Historical Volatility 39.92%
  • IV Percentile 95%
  • IV Rank 61.97%
  • IV High 201.21% on 01/22/25
  • IV Low 18.50% on 09/26/24
  • Put/Call Vol Ratio 365.91
  • Today's Volume 4,036
  • Volume Avg (30-Day) 349
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 8,537
  • Open Int (30-Day) 9,375

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.55
  • Number of Estimates 2
  • High Estimate -0.52
  • Low Estimate -0.58
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -685.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.85 +6.59%
on 04/09/25
Period Open: 4.98
5.16 -20.39%
on 03/17/25
-0.88 (-17.60%)
since 03/11/25
3-Month
3.85 +6.59%
on 04/09/25
Period Open: 4.60
5.19 -20.93%
on 03/06/25
-0.50 (-10.79%)
since 01/10/25
52-Week
3.85 +6.59%
on 04/09/25
Period Open: 4.28
6.75 -39.20%
on 06/13/24
-0.18 (-4.12%)
since 04/11/24

Most Recent Stories

More News
Vanda: Q4 Earnings Snapshot

Vanda: Q4 Earnings Snapshot

VNDA : 4.09 (+0.25%)
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Shares of Kodiak Sciences KOD have skyrocketed 270.7% in the past six months fueled by updates from the developmental program of its lead investigational candidate, tarcocimab. It is a novel anti-VEGF...

KOD : 2.14 (+2.15%)
CTMX : 0.4914 (-0.65%)
CSTL : 19.59 (+1.50%)
VNDA : 4.09 (+0.25%)
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

The year 2024 has been a mixed ride for the biotech industry. It started on a positive note, attracting investors’ attention in areas with great commercial potential, like obesity, immunology and gene...

ALLO : 1.3650 (-0.36%)
RZLT : 2.48 (+0.40%)
VNDA : 4.09 (+0.25%)
New Strong Buy Stocks for November 14th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Vanda Pharmaceuticals Inc. VNDA: This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings...

TSQ : 6.88 (-0.86%)
SPPJY : 1.6700 (-13.02%)
VMEO : 4.80 (-1.64%)
TBI : 4.36 (-0.68%)
VNDA : 4.09 (+0.25%)
Vanda: Q3 Earnings Snapshot

Vanda: Q3 Earnings Snapshot

VNDA : 4.09 (+0.25%)
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.Here's...

JAZZ : 100.71 (-1.31%)
EXEL : 34.47 (+0.03%)
NVAX : 5.65 (+4.05%)
VNDA : 4.09 (+0.25%)
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today

A regulator's decision drained the market's enthusiasm for the company.

VNDA : 4.09 (+0.25%)
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment

New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves targeted...

ALZN : 0.7701 (+0.01%)
VNDA : 4.09 (+0.25%)
ITCI : 131.87 (-0.04%)
TEVA : 13.04 (+1.72%)
ABBV : 171.00 (-1.84%)
Vanda: Q2 Earnings Snapshot

Vanda: Q2 Earnings Snapshot

VNDA : 4.09 (+0.25%)
Accenture, KB Home rise; Snap, Jabil fall, Thursday, 6/20/2024

Stocks that traded heavily or had substantial price changes on Thursday: Accenture, KB Home rise; Snap, Jabil fall

CG : 35.76 (-2.38%)
CMC : 41.44 (-0.98%)
VNDA : 4.09 (+0.25%)
DFS : 154.74 (-2.45%)
SNAP : 7.84 (+0.13%)
KBH : 50.61 (-1.54%)
ACN : 278.46 (-2.37%)
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies

Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET program that is evaluating the investigational anti-OX40 therapy rocatinlimab...

REGN : 545.97 (-0.08%)
AMGN : 279.91 (-0.53%)
SNY : 50.80 (+2.30%)
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Though the drugmaker had performed well since the beginning of the decade, it encountered issues that sank its...

REGN : 545.97 (-0.08%)
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

REGN : 545.97 (-0.08%)
SNY : 50.80 (+2.30%)
Is Regeneron Pharmaceuticals Stock Underperforming the Dow?

Regeneron Pharmaceuticals has underperformed the Dow over the past year, but analysts are highly optimistic about the stock’s prospects.

INCY : 55.35 (+0.33%)
$DOWI : 39,741.77 (+0.37%)
REGN : 545.97 (-0.08%)
Bayer Q4 Earnings In Line, Revenues Top on Nubeqa, Kerendia Sales

Bayer AG BAYRY reported fourth-quarter 2024 core earnings of 28 cents per American Depositary Receipt (ADR), in line with the Zacks Consensus Estimates. The company reported earnings of 50 cents per ADR...

BAYRY : 5.7700 (+2.49%)
JNJ : 149.03 (+0.23%)
REGN : 545.97 (-0.08%)
Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?

Vertex Pharmaceuticals has outperformed relative to the healthcare sector over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

VRTX : 479.89 (+0.93%)
IYH : 56.16 (+0.12%)
REGN : 545.97 (-0.08%)
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug

Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).The...

BMRN : 56.12 (-0.36%)
GILD : 101.92 (+0.51%)
REGN : 545.97 (-0.08%)
RHHBY : 37.2300 (+1.00%)
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

REGN : 545.97 (-0.08%)
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

NVO : 64.20 (+4.88%)
LLY : 726.88 (+0.83%)
REGN : 545.97 (-0.08%)
SNY : 50.80 (+2.30%)
Natera (NTRA) Q4 Earnings: What To Expect

Natera (NTRA) Q4 Earnings: What To Expect

NTRA : 144.91 (+1.14%)
EXAS : 42.97 (-1.76%)
REGN : 545.97 (-0.08%)
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies

Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET program that is evaluating the investigational anti-OX40 therapy rocatinlimab...

REGN : 545.97 (-0.08%)
AMGN : 279.91 (-0.53%)
SNY : 50.80 (+2.30%)
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Though the drugmaker had performed well since the beginning of the decade, it encountered issues that sank its...

REGN : 545.97 (-0.08%)
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

REGN : 545.97 (-0.08%)
SNY : 50.80 (+2.30%)
Is Regeneron Pharmaceuticals Stock Underperforming the Dow?

Regeneron Pharmaceuticals has underperformed the Dow over the past year, but analysts are highly optimistic about the stock’s prospects.

INCY : 55.35 (+0.33%)
$DOWI : 39,741.77 (+0.37%)
REGN : 545.97 (-0.08%)
Bayer Q4 Earnings In Line, Revenues Top on Nubeqa, Kerendia Sales

Bayer AG BAYRY reported fourth-quarter 2024 core earnings of 28 cents per American Depositary Receipt (ADR), in line with the Zacks Consensus Estimates. The company reported earnings of 50 cents per ADR...

BAYRY : 5.7700 (+2.49%)
JNJ : 149.03 (+0.23%)
REGN : 545.97 (-0.08%)
Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?

Vertex Pharmaceuticals has outperformed relative to the healthcare sector over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

VRTX : 479.89 (+0.93%)
IYH : 56.16 (+0.12%)
REGN : 545.97 (-0.08%)
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug

Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).The...

BMRN : 56.12 (-0.36%)
GILD : 101.92 (+0.51%)
REGN : 545.97 (-0.08%)
RHHBY : 37.2300 (+1.00%)
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

REGN : 545.97 (-0.08%)
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

NVO : 64.20 (+4.88%)
LLY : 726.88 (+0.83%)
REGN : 545.97 (-0.08%)
SNY : 50.80 (+2.30%)
Natera (NTRA) Q4 Earnings: What To Expect

Natera (NTRA) Q4 Earnings: What To Expect

NTRA : 144.91 (+1.14%)
EXAS : 42.97 (-1.76%)
REGN : 545.97 (-0.08%)

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

3rd Resistance Point 4.38
2nd Resistance Point 4.24
1st Resistance Point 4.16
Last Price 4.09
1st Support Level 3.93
2nd Support Level 3.79
3rd Support Level 3.71

See More

52-Week High 6.75
Fibonacci 61.8% 5.64
Fibonacci 50% 5.30
Fibonacci 38.2% 4.96
Last Price 4.09
52-Week Low 3.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.